Arcellx Dirección

Dirección controles de criterios 2/4

El CEO de Arcellx's es Rami Elghandour , nombrado en Jan 2021, tiene una permanencia de 3.25 años. compensación anual total es $24.96M, compuesta por 2.4% salario y 97.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.17% de las acciones de la empresa, por valor de $4.80M. La antigüedad media del equipo directivo y de la junta directiva es de 2.9 años y 3.7 años, respectivamente.

Información clave

Rami Elghandour

Chief Executive Officer (CEO)

US$25.0m

Compensación total

Porcentaje del salario del CEO	2.4%
Permanencia del CEO	3.3yrs
Participación del CEO	0.2%
Permanencia media de la dirección	3yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rami Elghandour en comparación con los beneficios de Arcellx?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$25m	US$601k	-US$71m
Sep 30 2023	n/a	n/a	-US$130m
Jun 30 2023	n/a	n/a	-US$183m
Mar 31 2023	n/a	n/a	-US$190m
Dec 31 2022	US$14m	US$565k	-US$189m
Sep 30 2022	n/a	n/a	-US$170m
Jun 30 2022	n/a	n/a	-US$95m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$23m	US$470k	-US$65m

Compensación vs. Mercado: La compensación total de Rami($USD24.96M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.59M).

Compensación vs. Ingresos: La compensación de Rami ha aumentado mientras la empresa no es rentable.

CEO

Rami Elghandour (44 yo)

3.3yrs

Permanencia

US$24,964,306

Compensación

Mr. Rami Elghandour serves as President, Chief Executive Officer and Chairman of the Board of Directors at Arcellx, Inc. since January 2021. Mr. Elghandour joined the Arcellx, Inc. on January 22, 2021. Pre...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Rami Elghandour	Chairman of the Board	3.3yrs	US$24.96m	0.17% $ 4.9m
Michelle Gilson	Chief Financial Officer	2yrs	US$3.55m	0.018% $ 499.6k
Christopher Heery	Chief Medical Officer	3.1yrs	US$3.86m	0.017% $ 470.7k
Narinderjeet Singh	Chief Technical Officer	2.6yrs	sin datos	sin datos
David Tice	Chief Scientific Officer	2.8yrs	sin datos	sin datos
Myesha Lacy	Chief Investor & Communications Officer	3.3yrs	sin datos	sin datos
Maryam Abdul-Kareem	General Counsel & Chief Legal Officer	1.9yrs	sin datos	sin datos
Kate Aiken	Chief People Officer	3.3yrs	sin datos	sin datos
Neeraj Teotia	Chief Commercial Officer	3.1yrs	US$2.00m	sin datos
Aileen Fernandes	Chief Business Officer	1.9yrs	sin datos	sin datos

3.0yrs

Permanencia media

46yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ACLX se considera experimentado (2.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rami Elghandour	Chairman of the Board	3.3yrs	US$24.96m	0.17% $ 4.9m
David Lubner	Independent Director	3.8yrs	US$359.67k	0.041% $ 1.1m
Ali Behbahani	Independent Director	9.3yrs	US$355.17k	0.00080% $ 22.5k
Jill Carroll	Independent Director	6.7yrs	US$353.67k	sin datos
Derek Yoon	Independent Director	4.1yrs	US$347.17k	sin datos
Olivia Ware	Independent Director	2yrs	US$343.67k	0% $ 0
Kavita Patel	Independent Director	2.4yrs	US$344.67k	0% $ 0

3.8yrs

Permanencia media

49yo

Promedio de edad

Junta con experiencia: La junta directiva de ACLX se considera experimentada (3.7 años de antigüedad promedio).

Arcellx Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Chairman of the Board recently sold US$2.4m worth of stock

Chairman of the Board notifies of intention to sell stock

Chairman of the Board recently sold US$1.6m worth of stock

Recent updates

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock

Consensus EPS estimates fall by 365%

Price target increased by 12% to US$47.56

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Price target increased by 9.2% to US$43.56

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.9% to US$42.33

Chief Medical Officer exercised options and sold US$404k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead Sciences, Inc.

Insider recently sold US$51k worth of stock

Insider recently sold US$51k worth of stock

Chief Medical Officer exercised options and sold US$231k worth of stock

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth

High number of new directors

Arcellx: The Best Is Yet To Come

Arcellx, Inc. announced delayed 10-Q filing

Arcellx GAAP EPS of -$0.88

Arcellx down 9% on day lock-up period ends

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

Arcellx, Inc.(NasdaqGS:ACLX) dropped from Russell 2000 Growth Index

Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

Arcellx, Inc. Announces New Positive Clinical Data from the Ongoing Phase 1 Expansion Study of Its Novel, Autologous, CART-ddBCMA Therapy

High number of new directors

Arcellx, Inc. Appoints Michelle Gilson as Chief Financial Officer

Arcellx, Inc. Announces Resignation of Lewis T. Williams from Board of Directors

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

High number of new directors

Arcellx, Inc. Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting

Arcellx Announces Pre-Clinical Data Presentation for ACLX-002 at the American Association for Cancer Research Annual Meeting 2022

High number of new directors

Arcellx, Inc. has completed an IPO in the amount of $123.75 million.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad